<DOC>
	<DOCNO>NCT02158169</DOCNO>
	<brief_summary>The aim study describe , real-life context , impact epoetin alpha biosimilar , Retacrit® , anaemia patient receive chemotherapy , accord concomitant iron supplementation .</brief_summary>
	<brief_title>Biosimilar Retacrit® Treatment Chemotherapy-induced Anaemia Oncology Haematology</brief_title>
	<detailed_description>This longitudinal , observational , prospective , multicentre , cohort study , conduct representative sample public and/or private hospital-based oncologist haematologist practice Metropolitan France .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patient , age 18 year old , see oncologist hematologist chemotherapy . Patients oncologist hematologist decide initiation epoetin alpha biosimilar treatment ( Retacrit® ) anemia . Patients inform computer process medical data right access correction . Patients hemoglobin concentration &gt; 11 g/dL . Patients transfuse within previous month . Patients hypersensitive erythropoietin one excipients . Patients participate participate previous month clinical trial field anaemia oncology . Patients refuse participate observational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>